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ABSTRACT
Acute Graft-versus-Host Disease (GvHD) remains a major complication of 
allogeneic haematopoietic stem cell transplantation, with a significant proportion of 
patients failing to respond to first-line systemic corticosteroids. Reliable biomarkers 
predicting disease severity and response to treatment are warranted to improve its 
management. Thus, we sought to determine whether pentraxin 3 (PTX3), an acute-
phase protein produced locally at the site of inflammation, could represent a novel 
acute GvHD biomarker. Using a murine model of the disease, we found increased 
PTX3 plasma levels after irradiation and at GvHD onset. Similarly, plasma PTX3 
was enhanced in 115 pediatric patients on day of transplantation, likely due to 
conditioning, and at GvHD onset in patients experiencing clinical symptoms of the 
disease. PTX3 was also found increased in skin and colon biopsies from patients with 
active disease. Furthermore, PTX3 plasma levels at GvHD onset were predictive of 
disease outcome since they resulted significantly higher in both severe and therapy-
unresponsive patients. Multiple injections of rhPTX3 in the murine model of GvHD 
did not influence the disease course. Taken together, our results indicate that PTX3 
constitutes a biomarker of GvHD severity and therapy response useful to tailor 
treatment intensity according to early risk-stratification of GvHD patients.
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INTRODUCTION
Acute Graft-versus-Host Disease (GvHD) still 
accounts for 15-30% of allogeneic stem cell transplant 
(HSCT)-related mortality [1]. Currently, diagnosis 
of GvHD still relies on the observation of clinical 
manifestations suggestive of the disease, with histological 
confirmation, whenever possible. Newly diagnosed 
patients commonly receive a first-line steroid treatment, 
with less than 50% of them, however, achieving a 
sustained response [2]. The outcome of steroid-refractory 
patients is particularly poor despite the introduction 
of several second- and third-line therapies [3]. In this 
scenario, early identification of patients at high risk 
of developing severe/non responsive GvHD would 
potentially improve disease management through prompt 
adoption of risk-tailored therapies. 
In recent years, measurement of GvHD-specific 
biomarkers in the plasma or serum of HSCT patients 
has emerged as a new diagnostic and prognostic 
tool [4, 5]. Several cytokines playing a major role in 
systemic inflammation such as IL-2 and TNF-α have 
been investigated [5]. Furthermore, soluble molecules 
associated with allogeneic donor T cell-mediated 
cytotoxicity on recipient tissues, such as Elafin [6], HGF 
[7] and REG3α [8], or related to T-cell activation and 
polarization, such as sTNFRI, sIL-2Rα [7] and ST2 [9, 10], 
have also been proposed as diagnostic GvHD biomarkers. 
Among the large number of possible molecules identified, 
a few have been validated in large cohorts of patients and 
eventually included in composite biomarker panels [11, 
12]. However, the identification of new, highly sensitive, 
and easily measurable GvHD biomarkers, which could 
then be validated in a homogeneous allo-HSCT setting, 
still remains an urgent clinical need. This is particularly 
true for pediatric patients where the likelihood of 
developing GvHD, the response to therapy, and non-
relapse mortality rates are quite different from adult 
populations [13].
The long pentraxin 3 (PTX3) is a component of 
the humoral arm of innate immunity with a recognized 
non-redundant role in the modulation of inflammation 
and in the protection against selected pathogens [14]. It 
is an acute-phase protein rapidly produced by vascular 
endothelial cells, mesenchymal cells, and fibroblasts, as 
well as by cells of innate immunity, such as monocytes 
and granulocytes, upon stimulation by pro-inflammatory 
cytokines, damaged tissue-derived signals, and microbial 
molecules [15]. Unlike other acute-phase proteins, such as 
C-reactive protein, which is almost exclusively produced 
by hepatocytes in response to inflammation, PTX3 is 
considered a highly sensitive marker of primary local 
activation of innate immunity and inflammation, thanks 
to its peculiar pattern of production. Data obtained in 
several inflammatory vascular and autoimmune disorders, 
such as cardiovascular diseases [16], rheumatoid arthritis 
[17], vasculitis [18], and psoriasis [19], have pointed to 
a role for PTX3 as inflammatory marker of vascular-bed 
involvement. In all these conditions, a correlation among 
PTX3 levels, clinical outcome, and disease activity could 
be clearly established [20, 21].
In this study, we explored PTX3 as a biomarker of 
acute GvHD firstly in a murine model of the disease and 
secondly by prospectively monitoring PTX3 plasma levels 
in a bi-centric cohort of 115 pediatric patients undergoing 
HSCT for hemato-oncological diseases. Furthermore, to 
pursue the design of patient-tailored GvHD therapies, we 
investigated the predictive power of PTX3 for disease 
severity and treatment response. Finally, we evaluated 
the potential role of PTX3 in GvHD pathogenesis taking 
advantage of a mouse model that recapitulates the human 
disease. 
RESULTS
PTX3 plasma levels increase over baseline on day 
0 and at disease onset in a mouse model of acute 
GvHD
To ascertain whether murine PTX3 (mPTX3) 
might represent a useful biomarker of GvHD severity, we 
measured PTX3 plasma levels in a murine model of acute 
GvHD. Interestingly, we observed a significant increase in 
plasma levels of mPTX3 following irradiation [43.4 ng/ml 
(SE = 4.17, n = 6) at day -1 vs 348.21 ng/ml (SE = 30.32, n 
= 6) at day 0, p < 0.001] (Figure 1A). Next, we measured 
mPTX3 plasma levels in either syngeneic or allogeneic 
transplanted mice until day +21 after transplantation. At 
day +2, mPTX3 plasma levels started decreasing in both 
syngeneic and allogeneic grafted mice, reaching a low 
peak at day +3 (Figure 1B). At day +4, mPTX3 plasma 
levels in allogeneic, but not syngeneic recipient mice, 
started rising again reaching a mean value of 329 ng/ml, 
(SE = 28.1, n = 5) at day +4 (Figure 1B). In particular, at 
day +6, when the first GvHD symptoms became evident 
(Figure 1C), mean mPTX3 plasma levels in allogeneic 
recipient mice were significantly higher than those of 
mice given a syngeneic graft [347.71 ng/ml (SE = 46.29, 
n = 5) vs 188.64 ng/ml (SE = 40.73, n = 5), p = 0.03, 
respectively]. The protein remained significantly higher in 
the allogeneic group until day +9, decreasing thereafter 
to levels comparable to those seen in syngeneic controls.
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Table 1: Patients’ characteristics
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PTX3 plasma levels increase after conditioning 
regimen in a cohort of pediatric patients 
undergoing allogeneic HSCT
In light of the results obtained in the murine system, 
we investigated PTX3 plasma levels in a cohort of 115 
pediatric patients undergoing HSCT to cure their hemato-
oncological diseases. Patients’ characteristics, including 
underlying disease, HSCT type, GvHD prophylaxis and 
its incidence are summarized in Table I. Figure 2A shows 
PTX3 plasma levels at the various sampling time points. 
In order to investigate the impact of conditioning 
regimen on PTX3 plasma levels, we compared PTX3 
median values at baseline and at time of HSCT in 96 
patients for whom both measurements were available. 
Interestingly, median PTX3 level significantly increased 
from a basal value of 7.16 ng/ml (range = 1.00; 42.57) to 
reach a value of 31.65 ng/ml (range = 2.84; 259.32) at day 
0, corresponding to a median relative change (RC) of 3.23 
(range = -0.71; 30.40, p < 0.0001) (Figure 2B). In addition, 
we analyzed the impact of known pre-transplant GvHD 
risk factors, namely conditioning regimen intensity, donor 
type, and HLA matching, on PTX3 plasma concentration. 
PTX3 plasma levels at HSCT were significantly higher 
in 18 patients who underwent reduced toxicity/intensity 
regimen (median RC = 7.29, range = 0.08; 30.40) as 
compared to those of 78 patients receiving myeloablative 
conditioning (MAC) regimen (median RC = 3.08, range 
= -0.71; 27.65, p = 0.014) (Figure 2C). In contrast, no 
significant differences were observed in PTX3 levels 
measured at day 0 when we evaluated HSCT recipients 
according to either donor type or HLA-matching. In 
detail, patients receiving transplantation from either a 
related (RD, n = 29) or unrelated donor (URD, n = 67) 
had a median RC of 3.22 (range = -0.38; 30.40) and 3.23 
(range = -0.71; 27.65) (p = 0.24), respectively (Figure 
2D). Likewise, median PTX3 RC of 74 patients with a 
HLA-matched donor was 3.20 (range = -0.71; 24.92) as 
compared to 3.24 (range = 0.03; 30.40) of 22 patients 
transplanted from an HLA-disparate donor (p = 0.38, 
Figure 2E). 
The increase in PTX3 protein levels was very 
similar in patients who either did or did not subsequently 
develop GvHD [median RC = 3.24 (range = -0.51; 30.40) 
vs 3.20 (range = -0.71; 27.88), p = 0.91, respectively], 
indicating that the increase in PTX3 levels at day 0 was 
not related to a higher risk of GvHD occurrence within 
day +100 (Figure S1). 
Plasma PTX3 increases at the onset of GvHD in 
pediatric patients and is abundantly produced in 
disease-affected tissues
In order to determine the role of PTX3 as potential 
GvHD biomarker, we analyzed PTX3 levels in children 
who either did or did not develop the disease within 100 
days after HSCT. As shown in Table 1, 77/115 patients 
(67%) developed acute GvHD within day +100, while 
38/115 (33%) did not (“No GvHD” group). The median 
time to disease onset was 23 days (range = 7; 64 days). 
PTX3 data were available at GvHD onset for 61/77 (79%) 
of patients. Noteworthy, the median PTX3 level at the 
onset of GvHD was 25.30 ng/ml (range = 5.15; 847.44), 
a value significantly higher than that of the “No GvHD” 
group [14.49 ng/ml (range = 5.10; 57.44), p = 0.004, 
Figure 3A]. Results did not change if samples collected 
in the course of any clinically proven infection were 
excluded (data not shown). Specifically, the median PTX3 
level in infection-free “no-GvHD” patients was 12.73 ng/
ml (range = 3.80-49.64 ng/ml), significantly lower than 
that of GvHD patients (p = 0.0013). 
To further investigate the role of PTX3 in acute 
GvHD, PTX3 protein production was analyzed by 
immunohistochemistry on tissues typically affected by the 
disease, such as skin, liver, and gut, obtained from HSCT 
patients with active GvHD (Figure 3B). Biopsies of normal 
tumor-adjacent tissues of cancer patients were used as 
non-GvHD control. Interestingly, as shown in Figure 3B, a 
basal perilymphatic expression of PTX3 could be detected 
in control skin (Panel i), while enhanced PTX3 production 
in the extracellular matrix was clearly observed in skin 
affected by GvHD (Panel ii). In contrast, PTX3 production 
was limited to the portal tract of non-GvHD control and 
GvHD livers (Panels iii, iv) and to rare hepatocytes in 
control liver (Panel iii). Furthermore, PTX3 was localized 
in the subepithelial extracellular matrix in both control and 
GvHD-involved colon (Panels v, vi). High PTX3 protein 
levels were further detected in inflammatory cells, such as 
macrophages (↑) and neutrophils (*) in GvHD-involved 
colon (Panels vi-a and vi-b). 
Repeated measurements of PTX3 plasma levels 
over time confirm the diagnostic relevance of 
PTX3 at GvHD onset, but do not provide overall 
prediction of GvHD development
Given that weekly measurements of PTX3 were 
taken from time of HSCT onwards, we also asked 
whether changes in PTX3 plasma levels at those planned 
time points could be prognostic of GvHD development. 
Supplemental Table S1 shows the median plasma PTX3 
values observed at various planned time point for patients 
who did or did not develop GvHD later during follow-up 
within 100 days. Both subgroups displayed comparable 
PTX3 plasma levels at day 0. During follow-up, in both 
subgroups, we observed a gradual decrease in PTX3 
plasma levels that never led to significant differences in 
median PTX3 values between the groups throughout the 
entire time course. 
We further investigated the prognostic role of the 
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Figure 1: Monitoring of mPTX3 in the plasma of C57Bl/6 mice given either syngeneic or allogeneic transplantation. 
C57Bl/6 mice irradiated with 900 Rad were inoculated intravenously with 107 bone marrow cells and 20 x 106 splenocytes derived from 
C56Bl/6 donor mice (syngeneic transplantation) or from Balb/c donors (allogeneic transplantation). Data from two independent experiments 
were pooled (syngeneic controls: n = 17; allogeneic transplanted mice: n = 18). A. mPTX3 plasma levels were evaluated before irradiation 
(basal, day -1) and on day 0, before transplantation. B. Syngeneic and allogeneic transplanted mice were prospectively monitored until day 
+21 after transplantation in terms of mPTX3 plasma levels (n≥ 5 mice per time point, per group) C. and GvHD clinical score. *p≤ 0.05; 
**p≤ 0.01¸ ***p≤ 0.001.
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Figure 2: Monitoring and analysis of PTX3 levels in the plasma of HSCT pediatric patients. A. Available PTX3 plasma 
levels measured on 115 patients before the beginning of conditioning regimen (basal), on day 0 (HSCT) and weekly until day +100 for 
patients not experiencing GvHD, or until disease occurrence for GvHD patients. B. Relative change (RC) of PTX3 concentration over 
baseline at day 0 in 96 patients where both measurements could be performed. RC was calculated as follows: day 0 RC = (day 0 PTX3- 
basal PTX3/ basal PTX3). The p-value indicates that RC at HSCT is significantly different from zero. C. PTX3 RC at day 0 measured 
according to the intensity of the conditioning regimen, D. the type of donor (RD = related donor, URD = unrelated donor), and E. the HLA-
matching in the donor/recipient pair (HLA-matched = matching ≥9/10 in the case of bone marrow or peripheral blood; = 6/6 in the case of 
cord blood). Each box-plot shows the median, the first and third quintiles and extends from the lowest to the highest value; extreme outliers 
are not shown, but were included in the calculations.
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Figure 3: PTX3 levels in the plasma of HSCT patients at disease onset and PTX3 protein production in biopsies from 
GvHD target organs. A. PTX3 plasma levels at the onset of acute GvHD (N = 61) and in plasma samples from “no GvHD” patients (N 
= 38). The box-plot shows the median, the first and third quintiles and extends from the lowest to the highest value; extreme outliers are 
not shown, but were included in the calculations. B. Immunohistochemical analysis of PTX3 expression on paraffin-embedded sections of 
skin (i, ii), liver (iii, iv) and gut (v, vi) from controls and GvHD patients. Scale bar = 50µm. Insert subpanels vi-a and vi-b show magnified 
macrophages (↑) and neutrophils (*) infiltrating the gut of a GvHD patient (scale bar = 20µm). 
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joint PTX3 pattern over time using two types of regression 
models. With the first model, we sought to ascertain 
whether the risk of GvHD during follow-up could be 
predicted using all available PTX3 readouts up to the 
most recent one before GvHD onset (i.e. the one measured 
in the previous week, as per planned sampling). This 
regression analysis did not reveal a significant relationship 
between the pattern of PTX3 plasma levels and the risk 
of GvHD (p-value = 0.71). In contrast, when the model 
considered all available PTX3 readouts which, for patients 
who developed GvHD, included the measurement at onset, 
it revealed that PTX3 had indeed a highly significant 
diagnostic relevance (p < 0.001), suggesting that the 
protein level rose at time of GvHD occurrence.
PTX3 plasma levels at GvHD onset are associated 
with disease severity
Next, we sought to determine whether PTX3 
plasma levels at onset could provide information on 
GvHD severity. Thus, we analyzed our cohort of patients 
according to the maximum clinical GvHD grade observed 
for each patient. PTX3 plasma levels at disease onset in 
patients with mild GvHD (i.e. maximum grade = I, N = 
21) were compared to those of patients with more severe 
disease (i.e. maximum grade II-IV, N = 40). Remarkably, 
the median PTX3 level at disease onset was 33.08 ng/ml 
(range = 5.15; 847.44) in the grade II-IV acute GvHD 
group, a value significantly higher than that observed in 
patients who developed mild acute GvHD, whose median 
PTX3 level was 15.69 (range = 7.27; 80.57, p = 0.0165, 
Figure 4A). The ROC curve for the prediction of grade 
II-IV GvHD showed an AUC (95% C.I.) of 0.69 [(0.56, 
0.83), Figure 4B].
PTX3 plasma levels at GvHD onset are predictive 
of poor response to therapy
In an effort to establish a relationship between PTX3 
and response to treatment, we measured PTX3 plasma 
levels in patients who were responsive or not to 4-week 
GvHD therapy. The median plasma level of PTX3 was 
3-fold higher at the time of disease onset in 10 patients 
who subsequently did not respond to therapy (61.47 ng/
ml, range = 7.83; 847.44) than that of 51 patients who 
displayed either complete or partial response (20.47 ng/ml, 
range = 5.15; 205.28, p = 0.0526) (Figure 5A). The ROC 
curve for the prediction of response to GvHD treatment 
showed an AUC (95% C.I.) of 0.70 [(0.48, 0.92), Figure 
5B].
Furthermore, we analyzed PTX3 levels at GvHD 
onset according to the survival status at 1 year after HSCT. 
Among 77 patients who developed GvHD, 16.9% (n = 13) 
died within the first year after HSCT. PTX3 measurements 
were available in 9 deceased and 52 surviving patients. As 
shown in Figure 5C, the median plasma level of PTX3 at 
GvHD onset was 76.31 ng/ml (range = 7.12; 847.44) in 
deceased patients. Although not significantly different, this 
value was more than 3-fold higher than that of surviving 
patients, whose median PTX3 plasma level was 22.72 ng/
ml (range = 5.15; 205.28, p = 0.16). 
PTX3 administration does not affect the course of 
GvHD in allogeneic transplanted mice
We also assessed in the mouse model whether PTX3 
could also play a role in disease pathogenesis. For this 
purpose, we performed repeated injections of recombinant 
human (rh)PTX3 in our mouse model of GvHD. In 
order to induce a mild disease, C57Bl/6 recipients were 
inoculated at day 0 with 7x106 BM cells and 5x106 
splenocytes from Balb/c along with i.p. rhPTX3 (n = 
15) or vehicle alone (n = 15) three times per week. As 
shown in Figure 6A, the extent of weight loss throughout 
the 67 day-period of observation in rhPTX3-treated and 
vehicle-treated mice was similar. Likewise, no differences 
were observed between the two groups in terms of overall 
GvHD score (Figure 6B). 
We next analyzed, at day +67, the appearance 
of histopathological lesions in skin, liver, and gut from 
mice treated or not with rhPTX3. As shown in Figure 
S1, no substantial differences were observed between 
mice that were injected or not with rhPTX3 in terms of 
scores attributed to each tissue sample (Figure S2A) as 
well as total score (Figure S2B). Consistent with the mild 
GvHD induced by our protocol, we observed moderate 
lymphocyte infiltration in skin, liver, and colon samples 
from either group (Figure 6C). Furthermore, we detected 
similar levels of mild epidermal hyperplasia in the skin 
of PTX3-treated and vehicle-treated mice (Figure 6C, top 
panels).
DISCUSSION
Despite improvement in donor selection and post-
transplant immunosuppression, acute GvHD still occurs 
in 30-90% of patients undergoing allogeneic HSCT and 
is associated with high mortality rates in those patients 
experiencing treatment-refractory disease. In particular, 
transplant-related mortality (TRM) has been estimated 
to be 46% in patients refractory to corticosteroid therapy 
and 16% in responders [22, 23]. Several ongoing clinical 
trials are evaluating the efficacy of other therapies relying 
on initial GvHD treatment in combination with other 
treatments originally used as second-line therapy, although 
the results have so far proved inconclusive ( [24, 25] and 
NCT00609609). 
Since PTX3, an acute-phase protein rapidly 
produced by vascular tissues as well as by cells of innate 
immunity in response to inflammation [14], is a rapid 
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Figure 4: PTX3 plasma levels at GvHD onset by disease severity. A. PTX3 plasma levels measured at GvHD onset in patients 
with mild disease (maximum GvHD grade = I, N = 21) and severe disease (maximum GvHD grade II-IV, N = 40). The box-plot shows the 
median, the first and third quintiles and extends from the lowest to the highest value; extreme outliers are not shown, but were included in 
the calculations. B. Receiver operating characteristic (ROC) curve for the prediction of grade II-IV GvHD severity. AUC = area under the 
curve; 95% C.I. = 95% confidence interval.
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Figure 5: PTX3 plasma levels at GvHD onset by therapy response and survival status at 1-year. A. PTX3 plasma levels 
at GvHD onset in patients not responding to anti-GvHD therapy (left, N = 10) and responding completely or partially (right, N = 51). B. 
Receiver operating characteristic (ROC) curve for the prediction of response to anti-GvHD therapy. AUC = area under the curve; 95% C.I. 
= 95% confidence interval. C. PTX3 plasma levels at GvHD onset by status at 1 year after HSCT. The box-plot shows the median, the first 
and third quintiles and extends from the lowest to the highest value; extreme outliers are not shown, but were included in the calculations.
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Figure 6: Impact of PTX3 administration on GvHD course in a murine model of the pathology. After total body irradiation 
on day -1, C57Bl/6 recipients were given 7x106 BM cells and 5x106 splenocytes from Balb/c donors in the presence of rhPTX3 three 
times a week (n = 15) or vehicle alone (n = 15). All mice, from both groups, survived at least until day +8, and the longest survivors were 
sacrificed at day +67. A. Weight was monitored in transplant recipients until day +67. Data are expressed as mean percentage of weight loss 
± standard error. B. Mean GvHD overall score ± standard error was calculated for both PTX3 and vehicle treated mice, until day +67. C. 
GvHD histopathological analysis were performed on hematoxylin-eosin stained sections of skin, liver and gut, obtained at day +67 from 
PTX3 treated mice (n = 5) and from vehicle treated mice (n = 5), as controls. One representative image per group is shown. Top and middle 
panels: (↑) intraepithelial lymphocytes, (*) degenerated epithelial cells. Bottom panels: BD = bile duct; PV = portal vein.
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and reliable marker for primary local activation of innate 
immunity and inflammation in several autoimmune 
disorders [17, 19], we sought to determine whether PTX3 
levels would change in the plasma of HSCT recipients 
and whether such changes could be used to predict 
GvHD severity and patient outcome as early as clinical 
manifestations appeared. The diagnostic value of such 
biomarker, in turn, would have allowed us to optimize 
risk stratification for the design of more effective tailored 
therapies.
Here, we report that PTX3 is dramatically 
upregulated in the plasma of syngeneic as well as of 
allogeneic transplanted mice within the first few hours 
of conditioning regimen. In good agreement with recent 
studies on radiation induced-vasculopathy [26], this rapid 
induction of plasma PTX3 levels could be attributed 
directly to the inflammatory response of vascular cells 
along with fibroblasts, epithelial cells, and endothelial 
cells undergoing irradiation. Interestingly, a second peak 
of PTX3 induction was only observed in the systemic 
circulation of allogeneic transplanted mice two days before 
the appearance of GvHD symptoms. We hypothesize that 
this increase in PTX3 plasma levels is likely triggered by 
massive ongoing production of inflammatory cytokines at 
peripheral sites, which precedes the observation of overt 
GvHD symptoms, including IL-1, and TNFα [27, 28], 
which are known to be potent inducers of PTX3 release. 
Of note, PTX3 plasma concentration started to decrease 
as the disease progressed. This observation is consistent 
with published work describing an early elevation of 
the pro-inflammatory cytokines IL-1α and TNFα in the 
serum of mice during the first week after transplantation, 
decreasing over time with concomitant GvHD progression 
and mortality [29]. 
Since PTX3 plays a crucial role in inflammation 
through activation of the complement cascade [30, 31] and 
inhibition of P-selectin-mediated neutrophil extravasation 
[32], we sought to establish a relationship between plasma 
levels of this protein and induction/resolution of GvHD 
lesions. The timely and continuous administration of 
PTX3 to allo-transplanted mice did not influence disease 
course as assessed by the presence of GvHD symptoms 
and by the histological analysis of disease-affected organs. 
Thus, PTX3 could represent an early sensor of GvHD-
related inflammation, whereas it does not appear to be 
directly involved in GvHD pathogenesis.
Based on data obtained from the mouse model, 
we investigated a potential role of PTX3 as a GvHD-
related biomarker in a bi-center cohort of 115 pediatric 
patients undergoing allogeneic HSCT. Consistent with our 
observations in the murine model, PTX3 plasma levels 
significantly augmented at day 0 compared with baseline 
values, most likely due to the conditioning regimen-
induced tissue damage. However, this increase did not 
correlate with known GvHD risk factors, such as the use 
of unrelated or HLA-disparate donors, nor it appeared 
to be predictive of a greater risk of developing acute 
GvHD. Unlike other validated GvHD biomarkers [33], 
PTX3 levels were higher on day 0 in patients receiving 
reduced-intensity conditioning (RIC) than in patients 
given a fully myeloablative regimen. This difference 
may be due to the persistence of recipient myeloid cells 
following RIC, which have been shown to produce high 
amounts of PTX3 in response to inflammatory stimuli 
[34]. Moreover, RIC patients were homogeneously treated 
with fludarabine, whose inflammatory effect on monocytes 
is well established [35]. 
Interestingly, PTX3 plasma levels, which 
progressively decreased toward baseline levels in the 
first few weeks after HSCT, readily increased at the onset 
of GvHD clinical signs. The high protein concentration 
in the systemic circulation mirrored PTX3 over-
production in GvHD target organs, as demonstrated by 
immunohistochemical analysis of skin and gastrointestinal 
lesions. While a basal perivascular and perilymphatic 
protein expression was detected in skin, liver, and colon 
biopsies from non-GvHD controls (Doni A., (IRCCS) - 
Humanitas Clinical and Research Center, Rozzano (MI), 
Italy, personal oral communication April 2016), PTX3 
accumulation was evident in GvHD inflamed dermal 
and colon extracellular matrix. Under this pathological 
condition, stromal cells, vascular cells as well as tissue-
infiltrating myeloid cells, which are well-known PTX3-
producers [15], could have all contributed to the release 
of PTX3 both in the skin as well as in the gut. Concerning 
the role of inflammatory effector cells, PTX3-expressing 
macrophages and neutrophils were detected in GvHD 
intestinal lesions. PTX3 was not specifically induced in 
GvHD hepatic lesions, in good agreement with previous 
data showing that the liver is not a source of PTX3 in 
inflammatory conditions [30]. 
PTX3 is an essential component of the innate 
immune response against several pathogens such as 
fungi and viruses [36, 37], which often cause severe 
and even fatal infections in the post-transplant period. 
Moreover, PTX3 plasma levels are significantly increased 
in different infectious conditions [38, 39]. Thus, we 
reasoned that PTX3 plasma level measurements could 
be somewhat affected by ongoing infections. However, 
when we compared PTX3 levels at GvHD onset with 
those measured in patients without GvHD, excluding 
plasma samples collected from patients suffering from 
clinically proven infections, we failed to notice significant 
differences from our previous analysis (data not shown), 
suggesting robustness of PTX3 as a biomarker for GvHD 
diagnosis at the onset of clinical symptoms. However, the 
full pattern of PTX3 readouts, collected at the planned 
time points up to the one before GvHD onset, could not 
predict subsequent GvHD occurrence.
Often the GvHD grade at onset is not representative 
of the ultimate disease severity, which usually becomes 
evident in 1-2 weeks. It is interesting to note that, in our 
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cohort of patients, PTX3 plasma levels correlated with 
the maximum overall grade of GvHD, which has been 
reported to reflect the progression of the disease after 
treatment [40] and to have a major impact on 2-year 
disease-free survival [41]. Moreover, patients with 
treatment-resistant GvHD had higher PTX3 levels at 
disease onset compared to responders. Likewise, patients 
who deceased within 1 year after HSCT showed higher 
protein levels at onset, although the difference was not 
statistically significant. Our data are in accordance with 
a recent paper from Doehn and collegues [42] showing 
that plasma PTX3 levels correlate with the occurrence and 
severity of acute GvHD in an adult cohort of transplanted 
patients.
Overall, these results suggest that PTX3 plasma 
level at GvHD occurrence is a robust onset biomarker 
and correlates with both maximum disease severity 
and response to treatment, both these characteristics 
being potentially useful to timely identify those patients 
who have a greater probability to die from GvHD, and 
who therefore could benefit from a more aggressive 
treatment already at the beginning of the disease [43, 44]. 
Conversely, our findings suggest that rapid steroid tapering 
should be considered in children with lower PTX3 plasma 
levels to avoid over-treating patients that are likely to 
develop a milder disease. This would also help reduce the 
risk of developing infectious disease associated with over-
treatment. Under current clinical practice, due to the lack 
of diagnostic tools for risk stratification, all GvHD patients 
receive the same corticosteroid-based therapy. In recent 
years, several reports have underscored the clinical need 
for a biomarker-based and patient-specific GvHD therapy 
in order to improve disease management [4, 33, 45]. For 
this purpose, large biomarker panels, believed to provide 
enough predictive/diagnostic performance, rather than 
single analytes, are currently under validation in defined 
cohort of HSCT patients [4, 10, 12]. 
Here, we have identified PTX3 as an easily 
measurable disease biomarker able to predict at onset of 
clinical symptoms, in a pediatric cohort of HSCT patients, 
the subsequent GvHD severity as well as the likelihood of 
refractoriness to standard therapy. 
Further studies are clearly needed to validate 
PTX3 as a biomarker that can predict GvHD severity and 
patient outcome in larger cohorts of HSCT recipients. 
The inclusion of PTX3 in a composite panel with other 
validated analytes will constitute a crucial step towards 
improving GvHD disease management. 
MATERIALS AND METHODS
Animals
Eight to ten week-old female C57BL/6 (B6, H2b) 
and Balb/c (H2d) mice were all obtained from Charles 
River Laboratories (Calco, Milan, Italy). For details, see 
the Supplemental Methods. 
GvHD mouse model
The GvHD mouse model was performed as 
previously described [46]. For details, please, see the 
Supplemental Methods. 
Effect of PTX3 administration on murine GvHD
For details, please, see the Supplemental Methods. 
Patients and samples
One-hundred-fifteen consecutive patients with 
hemato-oncological diseases, who underwent allogeneic 
HSCT at the Pediatric Depts. of “San Gerardo Hospital”, 
Monza and at “Regina Margherita Hospital”, Torino, Italy, 
were enrolled in the study. Further details are described in 
the Supplemental Methods.
Peripheral blood samples for PTX3 level 
measurement were collected before starting the 
conditioning regimen, on day 0 (i.e. at day of HSCT), 
weekly after HSCT (day +7, +14, +21, +28 ±3 days etc.) 
up to day +98 or to GvHD onset, whichever occurred 
first, and at GvHD onset (before the beginning of 
GvHD-specific drug therapy). Plasma was obtained after 
centrifuging whole blood, collected in EDTA containing 
Vacutainer tubes (Becton Dickinson), at 1000g for 10 
minutes. Plasma samples were then frozen at a minimum 
of -80°C until PTX3 was evaluated by ELISA assay, as 
previously reported [47].
Histology
Histological analyses of mouse and human tissues 
were performed as described in the Supplemental 
Methods.
Statistical analysis
GvHD mouse model
Student’s t test was used to evaluate the differences 
in terms of GvHD overall score and PTX3 plasma 
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concentration between different groups of mice. 
PTX3 levels in pediatric recipients of HSCT
 The overall impact of HSCT, as well as the impact 
of each single variable of the procedure (i.e. intensity of 
conditioning regimen, donor type, and HLA matching), on 
PTX3 plasma levels was determined by comparing PTX3 
levels at HSCT with PTX3 levels before conditioning 
(baseline). PTX3 relative change (RC) was obtained as 
follows: RC of PTX3 at HSCT = (PTX3 at HSCT - PTX3 
baseline)/PTX3 baseline, and tested by Wilcoxon rank-
sum test. In the cohort of patients with GvHD, the impact 
of PTX3 levels at onset of GvHD on its severity, response 
to therapy after 4 weeks, and survival status at day +360 
after HSCT were assessed by Wilcoxon rank-sum test, 
as well. The median PTX3 plasma level for “no GvHD” 
patients was calculated taking into account all available 
samples and was compared with the median plasma level 
of PTX3 measured at GvHD onset by Wilcoxon rank-sum 
test. The impact of PTX3 longitudinal pattern on the risk 
of GvHD was analyzed by means of a Cox regression 
model where the level of PTX3 was included as a time-
dependent covariate either with or without a lag time of 
one week. The regression coefficient was tested according 
to Wald. Logistic regression was applied to investigate 
the relationship between PTX3 levels at GvHD onset 
and the probability of developing grade II-IV GvHD 
and of responding to GvHD treatment. Subsequently, 
the receiver operating characteristic (ROC) curve was 
derived. The area under the curve (AUC) was estimated 
nonparametrically. All tests were two-sided. Analyses 
were performed with SAS 9.2.
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